This relationship suggests that higher PD-L1 expression may enhance ICI effectiveness, positioning PD-L1 as a crucial biomarker for predicting patient outcomes and guiding treatment strategies in cancer immunotherapy [6,7,8,9]. The gene discussed is CD274; the disease is cancer.